Prokarium
PrivateLast Round
Corporate Funding
Dec 2, 2025
Total Funding Raised
$73.87M
Company Overview
Prokarium operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Corporate Funding round in December 2025.
Prokarium is a biotechnology company that develops microbial immunotherapies for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Prokarium Comparables
Compare Prokarium with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Actym Therapeutics | 83% | |
| Vaxiion Therapeutics | 82% | |
| Shaoxing Salvectors Biotechnology Ltd. | 81% |
For institutional investors. Book with your work email.
Prokarium Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | Dec 2, 2025 | ||||
| Grant | Mar 14, 2024 | ||||
| Series C | Feb 9, 2023 | ||||
| Series B | Oct 27, 2020 | ||||
| Grant | Oct 8, 2019 | ||||
Series A | Feb 26, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Prokarium Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Korea Investment Partners | Series A |
| Flerie Invest | Series B, Series A, Series C |
| Innovate UK | Grant |
| SynbiCITE | Grant, Series C |
| Korea Investment Holdings | Series C |
| Biotechnology and Biological Sciences Research Council | Grant |
| Korea Investment Partners | Series A, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 21, 2026
Monthly visitors grew 238% MoM, from 317 to 1.1K.
- May 15, 2026
Will present interim clinical data at the 2026 AUA Annual Meeting.
For institutional investors. Book with your work email.
Prokarium Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Prokarium's valuation, stock price, and market status.
Is Prokarium a public or private company?
Prokarium is a private company.
What is the current stock price of Prokarium?
Prokarium is a private company, so its shares have no public market price. Caplight tracks Prokarium's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Prokarium worth (valuation)?
Valuation information for Prokarium is not publicly available.
Can I buy Prokarium stock?
Prokarium shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Prokarium's last funding round?
Prokarium's most recent funding round was Corporate Funding on December 2, 2025.
Who are the main investors in Prokarium?
Key investors in Prokarium include Korea Investment Partners, Flerie AB, Korea Investment Partners, Wellcome Trust, Riyadh Valley Company.
Will Prokarium IPO soon?
No public IPO plans have been announced for Prokarium.
How can I track Prokarium secondary market activity?
Caplight tracks bids, offers, and trades in Prokarium's shares on secondary markets.